GlassScriptPhysician profile
Kathryn Annette Murphy
NPI 1881052488
$1,620.74
in general payments reported to CMS, 2019-2025
23 companies · $17.73 in 2025
The $17.73 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $934 · 2022: $558 · 2023: $38.33 · 2024: $72.73 · 2025: $17.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $128.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $259.90 | 2021-2023 | Mounjaro |
| Otsuka America Pharmaceutical, INC. | $231.78 | 2021-2024 | Rexulti |
| Glaxosmithkline, LLC. | $183.66 | 2021-2025 | Shingrix |
| Novo Nordisk INC | $174.77 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $115.06 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $99.49 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $86.74 | 2021 | |
| Abbvie INC. | $73.55 | 2021 | |
| Astellas Pharma US INC | $69.15 | 2021-2022 | |
| Amarin Pharma, INC. | $55.93 | 2021 | |
| Amgen INC. | $40.40 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.64 | 2024 | Advate |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.62 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $20.22 | 2022 | |
| Jazz Pharmaceuticals INC. | $19.01 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $18.71 | 2022 | |
| Lundbeck LLC | $17.67 | 2022 | |
| Abbott Laboratories | $16.84 | 2022 | |
| Esperion Therapeutics, INC. | $16.25 | 2021 | |
| Genentech USA, INC. | $14.35 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $13.78 | 2021 | |
| Pfizer INC. | $13.60 | 2021 | |
| Phadia US INC. | $11.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.